- Home
- TLSI vs CDXS Comparison
TLSI vs CDXS Comparison
Compare TLSI & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- CDXS
- Stock Information
- Founded
- TLSI 2010
- CDXS 2002
- Country
- TLSI United States
- CDXS United States
- Employees
- TLSI N/A
- CDXS N/A
- Industry
- TLSI Medical Specialities
- CDXS Major Chemicals
- Sector
- TLSI Health Care
- CDXS Industrials
- Exchange
- TLSI Nasdaq
- CDXS Nasdaq
- Market Cap
- TLSI 244.3M
- CDXS 216.6M
- IPO Year
- TLSI N/A
- CDXS 2010
- Fundamental
- Price
- TLSI $4.73
- CDXS $2.56
- Analyst Decision
- TLSI Strong Buy
- CDXS Buy
- Analyst Count
- TLSI 4
- CDXS 2
- Target Price
- TLSI $11.13
- CDXS $11.00
- AVG Volume (30 Days)
- TLSI 118.6K
- CDXS 538.3K
- Earning Date
- TLSI 11-13-2025
- CDXS 10-30-2025
- Dividend Yield
- TLSI N/A
- CDXS N/A
- EPS Growth
- TLSI N/A
- CDXS N/A
- EPS
- TLSI N/A
- CDXS N/A
- Revenue
- TLSI $35,990,000.00
- CDXS $57,164,000.00
- Revenue This Year
- TLSI $56.79
- CDXS $12.88
- Revenue Next Year
- TLSI $54.15
- CDXS $21.64
- P/E Ratio
- TLSI N/A
- CDXS N/A
- Revenue Growth
- TLSI 45.50
- CDXS N/A
- 52 Week Low
- TLSI $3.42
- CDXS $1.90
- 52 Week High
- TLSI $5.88
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- TLSI 48.36
- CDXS 51.47
- Support Level
- TLSI $4.42
- CDXS $2.41
- Resistance Level
- TLSI $4.67
- CDXS $2.73
- Average True Range (ATR)
- TLSI 0.23
- CDXS 0.12
- MACD
- TLSI -0.03
- CDXS 0.03
- Stochastic Oscillator
- TLSI 61.87
- CDXS 55.26
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.